PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study
The first-line treatment with PD-1/PD-L1 ICIs showed numerically better clinical efficacy than the traditional double-agent chemotherapy in patients with KRAS-mutated NSCLC, especially in PFS. Additionally, PD-L1 expression, C reactive protein, CEA, and NLR could serve as markers for predicting the efficacy of immunotherapy in patients with KRAS-mutated NSCLC.
Authors
- Tiansheng Sun (ORCID: https://orcid.org/0000-0002-4053-7297)
- Feng Xiao (ORCID: https://orcid.org/0000-0003-3195-853X)
- Chen Yang (ORCID: https://orcid.org/0000-0001-6011-4067)
- Qingzhong Liu (ORCID: https://orcid.org/0000-0002-2006-5413)
- Hao Tang (ORCID: https://orcid.org/0000-0003-1536-1944)
- K. Wei
Institutions
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Changzheng Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1186/s12885-025-13868-9
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27